These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22926062)

  • 1. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
    Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
    Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.
    Tongu M; Harashima N; Tamada K; Chen L; Harada M
    Cancer Sci; 2015 Jan; 106(1):9-17. PubMed ID: 25363339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
    Le HK; Graham L; Cha E; Morales JK; Manjili MH; Bear HD
    Int Immunopharmacol; 2009 Jul; 9(7-8):900-9. PubMed ID: 19336265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma.
    Tongu M; Harashima N; Yamada T; Harada T; Harada M
    Cancer Immunol Immunother; 2010 May; 59(5):769-77. PubMed ID: 19940990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
    Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
    J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.
    Sumida K; Wakita D; Narita Y; Masuko K; Terada S; Watanabe K; Satoh T; Kitamura H; Nishimura T
    Eur J Immunol; 2012 Aug; 42(8):2060-72. PubMed ID: 22653638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
    Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S
    Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
    Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.
    Esaki S; Goshima F; Kimura H; Murakami S; Nishiyama Y
    Int J Cancer; 2013 Apr; 132(7):1592-601. PubMed ID: 22949155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenic chemotherapy in two mouse colon cancer models.
    Taniura T; Iida Y; Kotani H; Ishitobi K; Tajima Y; Harada M
    Cancer Sci; 2020 Oct; 111(10):3527-3539. PubMed ID: 32816355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro.
    Kan S; Hazama S; Maeda K; Inoue Y; Homma S; Koido S; Okamoto M; Oka M
    Anticancer Res; 2012 Dec; 32(12):5363-9. PubMed ID: 23225438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice.
    Rearte B; Maglioco A; Balboa L; Bruzzo J; Landoni VI; Laborde EA; Chiarella P; Ruggiero RA; Fernández GC; Isturiz MA
    Clin Exp Immunol; 2010 Dec; 162(3):568-77. PubMed ID: 20964639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
    Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
    Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
    Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
    J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inhibitory effects of a combination of rmhTRAIL and gemcitabine on human non-small cell lung cancer cell line NCI-H460 cells in vitro and in vivo].
    Tang CH; Liu XQ; Yang SF; Zhu B; Gao HJ
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):808-12. PubMed ID: 19173823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
    Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.
    Rasmussen RM; Kurzman ID; Biller BJ; Guth A; Vail DM
    Vet Comp Oncol; 2017 Jun; 15(2):421-430. PubMed ID: 26522053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models.
    Iida Y; Harashima N; Motoshima T; Komohara Y; Eto M; Harada M
    Cancer Sci; 2017 Oct; 108(10):1974-1984. PubMed ID: 28787548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.
    Manrique SZ; Dominguez AL; Mirza N; Spencer CD; Bradley JM; Finke JH; Lee JJ; Pease LR; Gendler SJ; Cohen PA
    Oncotarget; 2016 Jul; 7(28):42919-42942. PubMed ID: 27341020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
    Francia G; Shaked Y; Hashimoto K; Sun J; Yin M; Cesta C; Xu P; Man S; Hackl C; Stewart J; Uhlik M; Dantzig AH; Foster FS; Kerbel RS
    Mol Cancer Ther; 2012 Mar; 11(3):680-9. PubMed ID: 22188817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.